Lv31
208 积分 2025-11-04 加入
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1小时前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1小时前
已关闭
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
7天前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
9天前
已完结
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
13天前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
13天前
已完结
儿童白血病微小残留病监测与临床应用指南（2026）
21天前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
1个月前
已完结
Effects of B Cell Depletion by CD19‐Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis
1个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
皖公网安备34019202002308
